Revvity Achieves FDA Clearance for Innovative Testosterone Testing Immunoassay
- Revvity received FDA clearance for EUROIMMUN's first immunoassay test for direct measurement of free testosterone levels.
- The test delivers results in 48 minutes with a capacity of nearly 60 tests per hour, improving laboratory efficiency.
- Revvity emphasizes commitment to innovative diagnostic solutions, enhancing healthcare capabilities for conditions like hypogonadism and PCOS.
Revvity Pioneers Testosterone Testing with FDA Clearance for Innovative Immunoassay
Revvity, Inc. has made a significant advancement in the field of diagnostic testing with the announcement of its 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This groundbreaking achievement marks the first FDA-cleared test for the direct quantitative measurement of free testosterone levels, an essential metric for assessing various health conditions. With the ability to deliver results in just 48 minutes and a throughput capacity nearing 60 tests per hour, this test represents a transformative leap in both speed and efficiency for clinical laboratories.
The ChLIA test utilizes monoclonal antibodies, ensuring specificity and consistent performance across different test batches. This high-performance assay is designed to operate on EUROIMMUN’s iSYSTM and i10 TM instruments, which are known for their user-friendly interfaces and random-access capabilities. Such features allow for rapid turnaround times, reducing the workload on laboratory technicians and minimizing the need for extensive training. This innovation not only streamlines the testing process but also enhances the diagnostic capabilities for conditions such as hypogonadism, impotence, and polycystic ovarian syndrome (PCOS), which require accurate measurement of free testosterone levels for effective treatment planning.
Jonathan Friend, general manager at Revvity’s EUROIMMUN US, emphasizes that this FDA clearance aligns with the critical needs of laboratory customers seeking reliable and user-friendly testing solutions. As Revvity continues to expand its portfolio in diagnostic innovations, the company is well-positioned to meet the growing demands of healthcare providers and patients alike. This milestone is a testament to Revvity’s commitment to advancing health science through cutting-edge technology and innovative diagnostic solutions, further solidifying its reputation in the global healthcare landscape.
In addition to this major development, Revvity operates with a workforce of over 11,000 employees and anticipates revenues exceeding $2.7 billion for 2023. The company’s dedication to areas such as translational multi-omics technologies and biomarker identification ensures that Revvity remains at the forefront of the health sciences industry. Serving a diverse clientele that includes pharmaceutical, biotech, diagnostics, academia, and government sectors, Revvity is a recognized leader in delivering innovative health solutions worldwide.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

